Patients with symptomatic acquired long QT syndrome remain at significant arrhythmic risk when device-based protection cannot be fully established — either because implantable cardioverter-defibrillator (ICD) therapy is contraindicated or has been declined, or because recurrent shocks or syncope from ventricular arrhythmia continue despite optimised pharmacological management alongside an existing ICD.
In these circumstances, a specific intervention targeting the cardiac autonomic nervous system represents a recognised management option. The complete evidence-based regimen — including precise eligibility criteria, procedural pathway, and the full clinical algorithm — is detailed in the structured protocol.
DOI: 10.1093/eurheartj/ehac262
LCSD is indicated in patients with symptomatic LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on beta-blockers and genotype-specific drugs with an ICD and experiences multiple shocks or syncope due to VA.
View source ↗